Aficamten Shows Cardiac Structure Benefits in nHCM, Outperforms Metoprolol Across Subgroups
CYTK has more than doubled off its 52-week low of $35.22 on elevated volume (2.1× avg).
Summary
Cytokinetics presented additional analyses from two Phase 3 trials at ESC 2026. In ACACIA-HCM, aficamten improved diastolic function and reduced wall thickness in non-obstructive HCM, supporting a mechanism beyond symptom relief. A separate MAPLE-HCM post-hoc analysis showed consistent superiority over metoprolol regardless of prior beta-blocker use. These data strengthen the case for a supplemental NDA in nHCM, planned for Q4 2026, and broaden the drug's potential label. The company already reported positive primary results from ACACIA-HCM on August 28; today's release adds mechanistic and subgroup evidence that could influence regulatory review and commercial positioning.
At the time of this announcement, CYTK was trading at $73.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $35.22 to $88.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.